Research Progress of Targeted Therapy for BRAF Mutation
in Advanced Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2018.08.10
- Author:
Xia LIU
1
;
Diansheng ZHONG
1
Author Information
1. Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China.
- Publication Type:Journal Article
- Keywords:
Lung neoplasms;
Targeted therapy;
V-raf murine sar-coma viral oncogene homolog B1
- MeSH:
Carcinoma, Non-Small-Cell Lung;
drug therapy;
enzymology;
genetics;
pathology;
Drug Resistance, Neoplasm;
genetics;
Humans;
Lung Neoplasms;
drug therapy;
enzymology;
genetics;
pathology;
Molecular Targeted Therapy;
methods;
Mutation;
Proto-Oncogene Proteins B-raf;
genetics
- From:
Chinese Journal of Lung Cancer
2018;21(8):635-640
- CountryChina
- Language:Chinese
-
Abstract:
Targeted therapy is one of the major treatment modalities in advanced non-small cell lung cancer (NSCLC) with sensitive driver gene mutations. BRAF is considered a promising oncogenic driver in NSCLC after the discovery of epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) fusion and ROS1 rearrangement. BRAF V600E mutation accounts for more than half of BRAF mutations, which is a potential therapeutic target for advanced NSCLC. This review aims to summarize the advancements of BRAF gene mutation and targeted therapy for BRAF mutation in NSCLC.
.
